Statement from Penumbra, Inc. Regarding Results of MR CLEAN and Other Studies of Intra-Arterial Treatments at the International Stroke Conference 2015
NASHVILLE, Tenn. – February 11, 2015 – Penumbra, Inc., the market leader in intra-arterial stroke treatment, issued the following statement at the International Stroke Conference 2015 from Adam Elsesser, chairman and chief executive officer.
The landmark MR CLEAN study results are being presented for the first time in the U.S. at the International Stroke Conference 2015. MR CLEAN positively showed that intra-arterial stroke treatment, including thrombus retraction, aspiration or retrievable stent used at the discretion of the interventionalist, provides patients with superior outcomes compared to medical management with tissue plasminogen activator (tPA) alone, the current standard of care. MR CLEAN findings, which were also published in January in the New England Journal of Medicine, have the potential to change the standard of care and improve functional independence for the 15 million stroke patients worldwide who currently have few treatment options. Moreover, currently available technology continues to improve upon the baseline set by MR CLEAN.
With the results of MR CLEAN, as well as other open-label studies presented at ISC this week, we now have a growing, solid body of evidence showing that intra-arterial treatment should be made available to the millions of people around the world who suffer strokes each year. As a result, we are looking ahead to leading the needed transformation in stroke treatment delivery.
As a market leader in intra-arterial treatment, we are committed to improving patient outcomes through the ongoing innovation of new, advanced technology, as well as clinical and educational initiatives aimed at optimizing the delivery of care.
Penumbra, Inc. (www.penumbrainc.com) is a global interventional therapies company that develops and markets medical devices to treat challenging medical conditions suffering from significant unmet clinical need. Penumbra’s interventional therapies are used by specialist physician customers to treat patients in three clinical markets: neurovascular disease, peripheral vascular disease and neurosurgery. Penumbra has over 800 employees and its global headquarters is located in Alameda, California, with sales operations around the world.
Penumbra Media Relations: